Crossmark

Clinical Outcomes after Onset of Mirogabalin-Related Adverse Drug Reactions in Patients with Lumbar Spinal Stenosis: Post Hoc Analysis of the MiroTAS Study

Crossref DOI link: https://doi.org/10.1007/s40122-026-00855-6

Published Online: 2026-07-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nikaido, Takuya

Shiosakai, Kazuhito

Sakoda, Hiroshi
Funding

Funding for this research was provided by:

Daiichi-Sankyo
License Information

Text and Data Mining valid from 2026-07-18

Version of Record valid from 2026-07-18
More Information

Article History

Received: 27 March 2026

Accepted: 5 June 2026

First Online: 18 July 2026

Declarations

Conflict of Interest: Takuya Nikaido has received lecture fees from Daiichi Sankyo Co., Ltd. Kazuhito Shiosakai and Hiroshi Sakoda are employees of Daiichi Sankyo Co., Ltd.

Ethical Approval: The primary study was approved by the Clinical Research Review Committee, Fukushima Medical University Certified Review Board (CRB no. CRB2200002), which notified all participating centers of the approval. The primary study was conducted in accordance with the ethical principles, Clinical Trials Act, and relevant notifications stipulated in the Declaration of Helsinki (as revised in 2013). All patients provided written informed consent. The primary study was registered in the Japan Registry of Clinical Trials under identifier jRCTs021200007.

Document is current

Any future updates will be listed below